1 INTRODUCTION
1.1 OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MARKET SCOPE
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY DATA
1.3.2 PRIMARY DATA
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET BREAKDOWN AND DATA TRIANGULATION
1.4 STAKEHOLDERS
1.5 CURRENCY
1.6 RESEARCH ASSUMPTIONS
1.7 LIMITATION
2 EXECUTIVE SUMMARY
3 MARKET OUTLOOK
3.1 INTRODUCTION
3.2 DROC MATRIX
3.3 MARKET CHALLENGES
3.4 MARKET SHARE ANALYSIS
3.5 COST STRUCTURE ANALYSIS
3.6 VALUE CHAIN ANALYSIS
3.7 COVID-19 IMPACT ANALYSES
4 INDUSTRY TRENDS
4.1 INTRODUCTION
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
4.3.1 DEGREE OF COMPETITION
4.3.2 BARGAINING POWER OF BUYERS
4.3.3 BARGAINING POWER OF SUPPLIERS
4.3.4 THREAT FROM SUBSTITUTES
4.3.5 THREAT FROM NEW ENTRANTS
5 DERMATOLOGY TYPE ANALYSIS
5.1 INTRODUCTION
5.2 HISTORICAL MARKET TYPE ANALYSIS, 2017-2021
5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
5.4 Y-O-Y GROWTH TREND ANALYSIS
5.5 MEDICAL DERMATOLOGY
5.6 SURGICAL DERMATOLOGY
5.7 PEDIATRIC DERMATOLOGY
5.8 COSMETIC DERMATOLOGY
5.9 CUTANEOUS LYMPHOMA
5.10 DERMATOIMMUNOLOGY
5.11 OTHERS
6 DERMATOLOGY MARKET DRUGS TYPE ANALYSIS
6.1 INTRODUCTION
6.2 HISTORICAL MARKET DRUGS TYPE ANALYSIS, 2017-2021
6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
6.4 Y-O-Y GROWTH TREND ANALYSIS
6.5 PRESCRIPTION-BASED DRUGS
6.6 OVER-THE-COUNTER DRUGS
7 DERMATOLOGY MARKET DISEASE ANALYSIS
7.1 INTRODUCTION
7.2 HISTORICAL MARKET DISEASE ANALYSIS, 2017-2021
7.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
7.4 Y-O-Y GROWTH TREND ANALYSIS
7.5 ACNE
7.6 DERMATITIS
7.7 PSORIASIS
7.8 SKIN CANCER
7.9 ROSACEA
7.10 ALOPECIA
7.11 OTHERS
8 DERMATOLOGY MARKET ROUTE OF ADMINISTRATION ANALYSIS
8.1 INTRODUCTION
8.2 HISTORICAL MARKET ROUTE OF ADMINISTRATION ANALYSIS, 2017-2021
8.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
8.4 Y-O-Y GROWTH TREND ANALYSIS
8.5 TOPICAL ADMINISTRATION
8.6 ORAL ADMINISTRATION
8.7 PARENTERAL ADMINISTRATION
9 DERMATOLOGY MARKET APPLICATION ANALYSIS
9.1 INTRODUCTION
9.2 HISTORICAL MARKET APPLICATION ANALYSIS, 2017-2021
9.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
9.4 Y-O-Y GROWTH TREND ANALYSIS
9.5 HOSPITAL
9.6 SKIN CLINICS
9.7 OTHERS
10 GLOBAL DERMATOLOGY REGIONAL ANALYSIS
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.2.3 Y-O-Y GROWTH TREND ANALYSIS
10.2.3.1 U.S.
10.2.3.2 Canada
10.2.3.3 Mexico
10.3 ASIA-PACIFIC
10.3.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.3.2 Y-O-Y GROWTH TREND ANALYSIS
10.3.2.1 China
10.3.2.2 Japan
10.3.2.3 Korea
10.3.2.4 India
10.3.2.5 Southeast Asia
10.4 MIDDLE EAST AND AFRICA
10.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.4.3 Y-O-Y GROWTH TREND ANALYSIS
10.4.3.1 Saudi Arabia
10.4.3.2 UAE
10.4.3.3 Egypt
10.4.3.4 Nigeria
10.4.3.5 South Africa
10.5 EUROPE
10.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.5.3 Y-O-Y GROWTH TREND ANALYSIS
10.5.3.1 Germany
10.5.3.2 France
10.5.3.3 UK
10.5.3.4 Russia
10.5.3.5 Italy
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2017-2021
10.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2022–2031
10.6.3 Y-O-Y GROWTH TREND ANALYSIS
10.6.3.1 Brazil
10.6.3.2 Argentina
10.6.3.3 Columbia
11 COUNTRY LEVEL ANALYSIS
11.1 UNITED STATES
11.2 CANADA
11.3 MEXICO
11.4 CHINA
11.5 JAPAN
11.6 INDIA
11.7 KOREA
11.8 SAUDI AREBIA
11.9 UAE
11.10 EGYPT
11.11 NIGERIA
11.12 SOUTH AFRICA
11.13 GERMANY
11.14 FRANCE
11.15 UK
11.16 RUSSIA
11.17 ITALY
11.18 BRAZIL
11.19 ARGENTINA
11.20 COLUMBIA
12 MARKET PLAYERS
12.1 ABBVIE INC. (ALLERGAN PLC).
12.1.1 BUSINESS OVERVIEW:
12.1.2 PRODUCT PORTFOLIO
12.1.3 RECENT DEVELOPMENTS
12.1.4 SWOT ANALYSIS:
12.2 AMGEN INC.
12.3 GALDERMA
12.4 GLAXOSMITHKLINE PLC.
12.5 JOHNSON & JOHNSON SERVICES INC
12.6 LEO PHARMA A/S
12.7 NOVARTIS AG
12.8 ORGANON & CO (MERCK)
12.9 PFIZER INC.
12.10 SUN PHARMACEUTICAL INDUSTRIES LIMITED.
12.11 TAKEDS PHARMACEUTICAL
12.12 ROIVANT SCIENCES INC.
12.13 DERMBIONT
13 ABOUT US

TABLE 1 DERMATOLOGY REGIONAL HISTORICAL MARKET ANALYSIS, 2017–2021 (USD MILLION)
TABLE 2 GLOBAL DERMATOLOGY MARKET, 2022–2031, (USD MILLION)
TABLE 3 DERMATOLOGY CURRENT AND FUTURE REGIONAL ANALYSIS, 2022–2031 (USD MILLION)
TABLE 4 GLOBAL DERMATOLOGY HISTORICAL MARKET TYPE ANALYSIS, 2017-2021, (USD MILLION)
TABLE 5 DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 6 GLOBAL DERMATOLOGY HISTORICAL MARKET DRUGS TYPE ANALYSIS, 2017-2021, (USD MILLION)
TABLE 7 DERMATOLOGY CURRENT AND FUTURE DRUGS TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 8 GLOBAL DERMATOLOGY HISTORICAL MARKET DISEASE ANALYSIS, 2017-2021, (USD MILLION)
TABLE 9 DERMATOLOGY CURRENT AND FUTURE DISEASE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 10 GLOBAL DERMATOLOGY HISTORICAL MARKET ROUTE OF ADMINISTRATION ANALYSIS, 2017-2021, (USD MILLION)
TABLE 11 DERMATOLOGY CURRENT AND FUTURE ROUTE OF ADMINISTRATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 12 GLOBAL DERMATOLOGY HISTORICAL MARKET APPLICATION ANALYSIS, 2017-2021, (USD MILLION)
TABLE 13 DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 14 NORTH AMERICA DERMATOLOGY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 15 NORTH AMERICA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 16 NORTH AMERICA DERMATOLOGY CURRENT AND FUTURE DRUGS TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 17 NORTH AMERICA DERMATOLOGY CURRENT AND FUTURE DISEASE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 18 NORTH AMERICA DERMATOLOGY CURRENT AND FUTURE ROUTE OF ADMINISTRATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 19 NORTH AMERICA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 20 U.S. DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2017–2023
TABLE 21 U.S. DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 22 U.S. DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 23 CANADA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 24 CANADA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 25 MEXICO DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 26 MEXICO DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 27 APAC DERMATOLOGY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 28 ASIA-PACIFIC DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 29 ASIA-PACIFIC DERMATOLOGY CURRENT AND FUTURE DRUGS TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 30 ASIA-PACIFIC DERMATOLOGY CURRENT AND FUTURE DISEASE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 31 ASIA-PACIFIC DERMATOLOGY CURRENT AND FUTURE ROUTE OF ADMINISTRATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 32 ASIA-PACIFIC DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 33 CHINA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 34 CHINA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 35 JAPAN DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 36 JAPAN DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 37 KOREA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 38 KOREA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 39 INDIA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 40 INDIA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 41 SOUTHEAST ASIA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 42 SOUTHEAST ASIA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA DERMATOLOGY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA DERMATOLOGY CURRENT AND FUTURE DRUGS TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA DERMATOLOGY CURRENT AND FUTURE DISEASE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA DERMATOLOGY CURRENT AND FUTURE ROUTE OF ADMINISTRATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 49 SAUDI ARABIA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 50 SAUDI ARABIA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 51 UAE DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 52 UAE DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 53 EGYPT DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 54 EGYPT DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 55 NIGERIA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 56 NIGERIA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 57 SOUTH AFRICA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 58 SOUTH AFRICA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 59 EUROPE DERMATOLOGY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 60 EUROPE DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 61 EUROPE DERMATOLOGY CURRENT AND FUTURE DRUGS TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 62 EUROPE DERMATOLOGY CURRENT AND FUTURE DISEASE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 63 EUROPE DERMATOLOGY CURRENT AND FUTURE ROUTE OF ADMINISTRATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 64 EUROPE DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 65 GERMANY DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 66 GERMANY DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 67 FRANCE DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 68 FRANCE DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 69 UK DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 70 UK DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 71 RUSSIA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 72 RUSSIA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 73 ITALY DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 74 ITALY DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 75 SOUTH AMERICA DERMATOLOGY HISTORICAL MARKET ANALYSIS, 2017-2021, (USD MILLION)
TABLE 76 SOUTH AMERICA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 77 SOUTH AMERICA DERMATOLOGY CURRENT AND FUTURE DRUGS TYPE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 78 SOUTH AMERICA DERMATOLOGY CURRENT AND FUTURE DISEASE ANALYSIS, 2022–2031 (USD MILLION)
TABLE 79 TABLE 82 SOUTH AMERICA DERMATOLOGY CURRENT AND FUTURE ROUTE OF ADMINISTRATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 80 SOUTH AMERICA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031 (USD MILLION)
TABLE 81 BRAZIL DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 82 BRAZIL DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 83 ARGENTINA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 84 ARGENTINA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)
TABLE 85 COLUMBIA DERMATOLOGY CURRENT AND FUTURE TYPE ANALYSIS, 2022–2031, (USD MILLION)
TABLE 86 COLUMBIA DERMATOLOGY CURRENT AND FUTURE APPLICATION ANALYSIS, 2022–2031, (USD MILLION)